
April 24, 2026
Children's Mercy has signed an exclusive licensing agreement with Vima Therapeutics for a new oral therapy targeting dystonia and Parkinson's disease. The drug candidate has received Fast Track status from the U.S. Food and Drug Administration.
Read more →
April 17, 2026
A new study led by Cincinnati Children’s shows most newborns avoid severe E. coli infections thanks to maternal antibodies transferred during pregnancy. Researchers plan further work on screening tests and potential probiotic interventions.
Read more →
Sign-up for the Weekly Newsletter from KC Reporter.